Company news

MeiraGTx Holdings plc news in 2025

MeiraGTx Holdings plc's news releases, calls and decks from 2025, newest first.

View company

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

November 12, 2025

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

November 9, 2025

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

October 6, 2025

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

August 13, 2025

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 12, 2025

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 12, 2025

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 8, 2025

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

March 12, 2025

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

March 12, 2025

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

February 20, 2025

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

January 21, 2025

Decks in 2025